4 results about "Anti cd19" patented technology

The present disclosure provides CD19 / CD20-binding domains and chimeric antigen receptors (CARs) based on the same, as well as corresponding nucleic acid molecules, vectors, cells, compositions, methods and uses, e.g., for the prevention and / or treatment of cancer and / or autoimmune disease.

The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a BCL-2 inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia.

The present invention provides to develop novel chimeric antigen receptor (CAR) encoded by an open reading frame 3 (ORF3) mRNA and amino acid sequences of any one of SEQ ID NO: 1 to SEQ ID NO: 109 specific to CD19 against hematologic malignancies associated with expression of Cluster of Differentiation 19 (CD19). The invention relates to the design of a synthetic CAR mRNA sequence comprising hu anti CD19 scFv, a hinge, a Transmembrane domain, a co-stimulatory domain and a CD3ζ signaling domain, where with the costimulatory is CD27 or 41BB for targeting and destroying malignant B-cells. This disclosure features anti-CD19 CAR T-cell therapy for antigen binding domains, directed to B cell malignancies, described herein.

The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a BCL-2 inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia.